Study Opened since 01 September 2010 and Studies to be opened soon

EORTC trial 40071

Effectiveness of first line treatment with lapatinib and ECF/X in metastatic gastric cancer according to HER2 and EGFR status: a randomized phase II trial. (Target Accrual: 228 patients)

Study Coordinator:

  • Arnaud Roth – Hôpital Cantonal Universitaire De Genève, Genève

Studies to be opened soon (in regulatory process)

EORTC trial 26081 – 22086

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with Newly Diagnosed Anaplastic Oligodendroglioma or Anaplastic Mixed Glioma with Chromosomal Co-delections of 1p and 19q. (Target Accrual: 544 patients)

Study Coordinators:

  • Martin J. Van den Bent – Erasmus University Medical Center, Rotterdam
  • Frederic Dhermain – Institut Gustave Roussy, Villejuif
  • Wolfgang Wick – Universitaetsklinikum Heidelberg – Kopfklinik, Heidelberg

EORTC trial 26091

Randomized trial assessing the significance of Bevacizumab in recurrent grade II and grade III gliomas. (Target Accrual: 144 patients)

Study Coordinators:

  • Martin van den Bent – Erasmus University Medical Center, Rotterdam
  • Ahmed Idbaih – CHU Pitié-Salpêtrière, Paris

EORTC trial 10085

Clinical and biological characterization of Male Breast Cancer: an international retrospective EORTC, BIG and NABCG intergroup study. (Target Accrual: 1800 patients)

Study Coordinator:

  • Fatima Cardoso – Institut Jules Bordet – Brussels

EORTC trial 58081

Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL). (Target Accrual: This trial is a prospective observational – biobanking study)

Study Coordinators:

  • Helene Cave, Hôpital Robert Debre (AP-HP), Paris
  • Yves Benoit, Universiteit Gent, Gent

EORTC trial 22071-24071

Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence. (Target Accrual: 800 patients for the main study, 150 patients for the pre-study)

Study Coordinators:

  • Wilfried Budach – Heinrich-Heine Universitaetsklinik Dusseldorf, Duesseldorf
  • Johannes Langendijk – University Medical Center Groningen, Groningen
  • Carla Van Herpen – Radboud University Nijmegen Medical Center, Nijmegen

EORTC trial 62091

A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma. (Target Accrual: 340 patients)

Study Coordinator:

  • Binh Bui-Nguyen – Institut Bergonie, Bordeaux

EORTC trial 06083 HOVON 100 ALL

Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial. A joint study of the HOVON (Hemato-Oncologie voor Volwassenen Nederland) and the EORTC. (Target Accrual: 340 patients)

Study Coordinators:

  • Simon Daenen – University Medical Center Groningen
  • Boris Labar – University Hospital Zagreb
  • A.W. Rijneveld – Erasmus MC, Rotterdam

EORTC trial 08092

Double blind randomized phase III study of maintenance Pazopanib versus placebo in Non Small Cell Lung Cancer patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung group study. (Target Accrual: 600 patients)

Study Coordinator:

  • Mary O’Brien – Royal Marsden Hospital, Sutton

 John Bean

Back to news list